Skip to main
INBX

INBX Stock Forecast & Price Target

INBX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inhibrx Biosciences is well-positioned to succeed in the market with their innovative pipeline, strong leadership team, and promising clinical trial data. Their drugs INBRX-106 and ozekibart have shown potential for various cancer types, and the ongoing Phase 3 trial for ozekibart is a positive indicator of the company's commitment to developing effective therapies. However, there are also risks involved in the commercialization and regulatory process that could potentially impact the company's success. It is evident that Inhibrx Biosciences has a strong pipeline, innovative technology, and experienced leadership team, which are important factors in the biopharmaceutical industry. Their drugs have shown promising results and the ongoing Phase 3 trial for ozekibart is a positive indicator of the company's dedication to developing effective therapies. However, there are risks involved in the commercialization process and regulatory requirements that may affect the company's success, which should be carefully monitored.

Bears say

Inhibrx Biosciences is facing challenges in competing with other drug developers for its potential treatments, particularly in the rare condition of chondrosarcoma. Despite the potential success of INBRX-106 in treating head and neck cancer, it may face difficulties in gaining market share due to the competition and high initial treatment cost. Furthermore, the risk of asymptomatic liver toxicity in patients and the challenges in clinical trials for rare conditions could further hinder the company's financial growth.

INBX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inhibrx Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inhibrx Biosciences Inc (INBX) Forecast

Analysts have given INBX a Strong Buy based on their latest research and market trends.

According to 2 analysts, INBX has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $197.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $197.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inhibrx Biosciences Inc (INBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.